Cabaletta Bio, Inc. disclosed unaudited cash balance of $241 million as of December 31, 2023, which includes proceeds from the sale of common stock. The company also provided corporate updates on Fast Track Designations, clinical trials, preclinical portfolio expansion, and cash runway.